In the span of eight months, Big Pharma companies took over four of the hottest radiopharmaceutical players in the industry.

Mendaera has found a leader with deep medical robotics experience to lead its commercialization push. Eric Davidson has taken ...

When the BIOSECURE Act hit a setback and missed the chance of becoming law in 2024, the deceleration of the draft legislation ...

In a phase 3 trial, Tenpoint Therapeutics’ eye drop—a combination of carbachol and brimonidine—improved vision for patients ...

Despite weathering significant criticism from lawmakers and patient groups over the steep cost of its rare disease med ...

Havas is forging deeper into the GLP-1 space with a series of YouTube videos about the drug class and its impact on the world ...

Beyond the influence of new therapies on drug pricing trends, Cowen’s report also accounted for the effects of legislation ...

The FDA will require GSK and Pfizer to include on the label of their respiratory syncytial virus (RSV) vaccines a warning ...

Welcome to Fierce Pharma's regulatory tracker for the first half of 2025. | In this tracker, Fierce Pharma is recording the ...

GlobalData has named heart failure as the next disease to feel the sales-boosting power of GLP-1 drugs. The analysts expect ...

Following a fresh round of job cuts in December, CDMO National Resilience is carrying its downsizing efforts into 2025. | ...

Anthem Biosciences, an India-based CDMO, submitted a filing (PDF) at the end of 2024 to announce its plans for a 33.95 ...